Sandra Orsulic

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. pmc Induction of ovarian cancer by defined multiple genetic changes in a mouse model system
    Sandra Orsulic
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Cancer Cell 1:53-62. 2002
  2. pmc A mouse model for the molecular characterization of brca1-associated ovarian carcinoma
    Deyin Xing
    Molecular Pathology Unit and Center for Cancer Research, Massachusetts General Hospital, Charlestown, Massachusetts 02129, USA
    Cancer Res 66:8949-53. 2006
  3. ncbi request reprint An RCAS-TVA-based approach to designer mouse models
    Sandra Orsulic
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Mamm Genome 13:543-7. 2002
  4. pmc A genetically defined mouse ovarian carcinoma model for the molecular characterization of pathway-targeted therapy and tumor resistance
    Deyin Xing
    Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA
    Proc Natl Acad Sci U S A 102:6936-41. 2005
  5. pmc Cyclooxygenase-1 is a potential target for prevention and treatment of ovarian epithelial cancer
    Takiko Daikoku
    Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, USA
    Cancer Res 65:3735-44. 2005
  6. pmc Modeling resistance to pathway-targeted therapy in ovarian cancer
    Deyin Xing
    Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
    Cell Cycle 4:1004-6. 2005
  7. pmc The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor
    Stephan Gasser
    Department of Molecular and Cell Biology and Cancer Research Laboratory, University of California, Berkeley, California 94720 3200, USA
    Nature 436:1186-90. 2005
  8. pmc Antiproliferative activity of sulforaphane in Akt-overexpressing ovarian cancer cells
    Devyani Chaudhuri
    Department of Microbiology and Immunology, New York Medical College, Room 331, Basic Sciences Building, Grasslands Reservation, Valhalla, NY 10595, USA
    Mol Cancer Ther 6:334-45. 2007
  9. ncbi request reprint Extracellular signal-regulated kinase is a target of cyclooxygenase-1-peroxisome proliferator-activated receptor-delta signaling in epithelial ovarian cancer
    Takiko Daikoku
    Department of Pediatrics, Division of Reproductive and Development Biology, Vanderbilt University Medical Center, Nashville, Tennessee 37232 2678, USA
    Cancer Res 67:5285-92. 2007
  10. pmc HOXB13 promotes ovarian cancer progression
    Jiangyong Miao
    Molecular Pathology Research Unit and Center for Cancer Research, Massachusetts General Hospital, Charlestown, MA 02129, USA
    Proc Natl Acad Sci U S A 104:17093-8. 2007

Collaborators

Detail Information

Publications12

  1. pmc Induction of ovarian cancer by defined multiple genetic changes in a mouse model system
    Sandra Orsulic
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Cancer Cell 1:53-62. 2002
    ..The induced ovarian tumors in mice resembled human ovarian carcinomas in their rapid progression and intraperitoneal metastatic spread...
  2. pmc A mouse model for the molecular characterization of brca1-associated ovarian carcinoma
    Deyin Xing
    Molecular Pathology Unit and Center for Cancer Research, Massachusetts General Hospital, Charlestown, Massachusetts 02129, USA
    Cancer Res 66:8949-53. 2006
    ..The Brca1 wild-type and Brca1-deficient mouse ovarian tumors and cell lines provide a new experimental system for the evaluation of therapies that target the Brca1 pathway...
  3. ncbi request reprint An RCAS-TVA-based approach to designer mouse models
    Sandra Orsulic
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Mamm Genome 13:543-7. 2002
  4. pmc A genetically defined mouse ovarian carcinoma model for the molecular characterization of pathway-targeted therapy and tumor resistance
    Deyin Xing
    Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA
    Proc Natl Acad Sci U S A 102:6936-41. 2005
    ..Tumors with alternative survival pathways may require the inactivation of multiple individual pathways for successful treatment...
  5. pmc Cyclooxygenase-1 is a potential target for prevention and treatment of ovarian epithelial cancer
    Takiko Daikoku
    Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, USA
    Cancer Res 65:3735-44. 2005
    ..The growth inhibitory effects of SC-560 result from reduced cell proliferation and/or accelerated apoptosis. Our results imply COX-1 as a target for the prevention and/or treatment of EOC...
  6. pmc Modeling resistance to pathway-targeted therapy in ovarian cancer
    Deyin Xing
    Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
    Cell Cycle 4:1004-6. 2005
    ....
  7. pmc The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor
    Stephan Gasser
    Department of Molecular and Cell Biology and Cancer Research Laboratory, University of California, Berkeley, California 94720 3200, USA
    Nature 436:1186-90. 2005
    ..Thus, the DNA damage response, previously shown to arrest the cell cycle and enhance DNA repair functions, or to trigger apoptosis, may also participate in alerting the immune system to the presence of potentially dangerous cells...
  8. pmc Antiproliferative activity of sulforaphane in Akt-overexpressing ovarian cancer cells
    Devyani Chaudhuri
    Department of Microbiology and Immunology, New York Medical College, Room 331, Basic Sciences Building, Grasslands Reservation, Valhalla, NY 10595, USA
    Mol Cancer Ther 6:334-45. 2007
    ....
  9. ncbi request reprint Extracellular signal-regulated kinase is a target of cyclooxygenase-1-peroxisome proliferator-activated receptor-delta signaling in epithelial ovarian cancer
    Takiko Daikoku
    Department of Pediatrics, Division of Reproductive and Development Biology, Vanderbilt University Medical Center, Nashville, Tennessee 37232 2678, USA
    Cancer Res 67:5285-92. 2007
    ..The ability of aspirin to inhibit EOC growth in vivo is an exciting finding because of its low cost, lack of cardiovascular side effects, and availability...
  10. pmc HOXB13 promotes ovarian cancer progression
    Jiangyong Miao
    Molecular Pathology Research Unit and Center for Cancer Research, Massachusetts General Hospital, Charlestown, MA 02129, USA
    Proc Natl Acad Sci U S A 104:17093-8. 2007
    ..Taken together, our results support a pro-proliferative and pro-survival role for HOXB13 in ovarian cancer...
  11. ncbi request reprint Mechanisms of Cables 1 gene inactivation in human ovarian cancer development
    Hideo Sakamoto
    Vincent Center for Reproductive Biology, Massachusetts General Hospital, Boston, Massachussetts 02114, USA
    Cancer Biol Ther 7:180-88. 2008
    ..Together these findings suggest that multiple mechanisms underlie the loss of Cables 1 expression in ovarian cancer cells, supporting the hypothesis that Cables 1 is a tumor suppressor in human ovarian cancer...
  12. pmc Hepsin colocalizes with desmosomes and induces progression of ovarian cancer in a mouse model
    Jiangyong Miao
    Molecular Pathology Unit and Center for Cancer Research, Massachusetts General Hospital, Charlestown, MA
    Int J Cancer 123:2041-7. 2008
    ..The ability of ectopic hepsin to induce tumor growth in mice is abrogated by the mutation of 3 critical residues in the catalytic domain, thus implicating the enzymatic activity of hepsin in promoting tumor progression...